Leonard Friedland | Vice President, Scientific Affairs And Public Health Vaccines, North America
GSK
Leonard Friedland is Vice President, Director Scientific Affairs and Public Health, Vaccines North America at GSK.
Dr. Friedland has held many positions in clinical research and development with GSK since 2003, specializing in infectious disease vaccination. Prior to his work at GSK, Dr. Friedland was Division Chief, Pediatric Emergency Medicine at Temple University School of Medicine, and attending physician in the Division of Emergency Medicine at Cincinnati Children’s Hospital Medical Center.
Dr. Friedland studied medicine at Mount Sinai School of Medicine in New York and conducted his residency in pediatrics at the Children's Hospital of Philadelphia and his fellowship in pediatric emergency medicine at St. Christopher's Hospital for Children, also in Philadelphia. He is currently a fellow and active member of the American Academy of Pediatrics.
At GSK, Dr. Friedland has led clinical research, health outcomes, and epidemiology teams, and has been directly involved in the development of all of GSK’s currently licensed and investigational vaccines. In his current role, Dr. Friedland is GSK’s primary medical and public health representative and spokesperson for US vaccine topics.
Appearances:
Pre-congress Workshops, April 6 @ 10:00
WORKSHOP H (FULL DAY): ANTI MICROBIAL RESISTANCE
Harmonizing national and international priorities – what is the role of public health and government in implementation AMR efforts? Collaborative strategies from industry to halting the AMR crisis – do we have a consistent message? 10:00 Workshop leader opening remarks10:10 Vaccines as Another Strategy to Reduce Antibiotic Resistance in Healthcare Settings10:40 Gaps in veterinary vaccines to address AMR11:10 Why do we think this is possible? Update on vaccine technology that is enabling better vaccinesPipeline updates from biotech and industry – alternatives from antibiotics11:40 TB vaccines12:10 Bacterial Vaccine Polypeptides12:25 Vaccine efforts in Acinetobacter baumannii12:40 Update on the development of a Klebsiella and Pseudomonas vaccineSign Up for Event Updates
Organiser
